A breakthrough in lung cancer - the biggest prize in immunotherapy

31st October 2014

A breakthrough in lung cancer - the biggest prize in immunotherapyAndrew McConaghie

AstraZeneca/MedImmune hopes its immunotherapy combinations will help it catch up with leaders.The exciting new generation of immuno-oncology drugs, led by Merck's Keytruda and Bristol-Myers Squibb's (BMS) Opdivo have arrived, and... Read more

Two critical factors to attain marketing excellence

30th October 2014

Two critical factors to attain marketing excellenceZoe Dunn

Companies need to commit to innovation and build meaningful, long-term relationships with patients to bring longer-term benefits on top of the short-term gains.How do brands know when they have achieved... Read more

Political dynamite - England’s Cancer Drugs Fund

29th October 2014

Political dynamite - England’s Cancer Drugs FundLeela Barham

Proposals to consider cost in decisions about what will, and, crucially, won't, be paid for by the Cancer Drugs Fund (CDF) in England are the latest changes in the controversial... Read more

Patient perspective: a fair price for life-extending drugs

28th October 2014

Patient perspective: a fair price for life-extending drugsSally Greenbrook

Today, most deaths in breast cancer are caused by secondary breast cancer. However, the high costs of drugs to slow its progress and the limits of the Cancer Drugs Fund... Read more


Bayer, Novo Nordisk report healthy third-quarter figures

31st October 2014

Bayer, Novo Nordisk report healthy third-quarter figuresStaff reporter

The third-quarter results season continues in a positive vein, with both Bayer and Novo Nordisk reporting higher revenues and profits.Bayer raised its forecasts for the year after putting in what... Read more

NICE draft guidance recommends dabigatran (Pradaxa) for blood clots

31st October 2014

NICE draft guidance recommends dabigatran (Pradaxa) for blood clotsLinda Banks

In draft guidance NICE has recommended the anti-blood clotting drug dabigatran (Pradaxa, Boehringer Ingelheim) as an option for treating and preventing recurrent and potentially fatal blood clots in the legs... Read more

Google thinks big with nanotechnology health 'moonshot'

30th October 2014

Google thinks big with nanotechnology health 'moonshot'Staff reporter

Google can never be faulted for thinking too small, but its latest healthcare project - a pill that diagnoses disease in its earliest stages - is particularly ambitious.The technology giant... Read more

Orphan drugs no longer niche

30th October 2014

Orphan drugs no longer nicheLinda Banks

By 2020 orphan drugs are expected to account for 19 per cent of the total share of prescription drug sales in the US, Japan and Europe, excluding generics, reaching $176... Read more

Audio & Video

Now on demand - real world insight into …

The Diabetes Debate


Now available on demand (free to access) - originally broadcast on October 29th 2014.

Non-adherence to self-management regimens in diabetes is globally... View more

On-demand webinar: Is pharma brand marke…

Kantar Health webinar

While pharma observers speculate on the death of outdated drug discovery and sales models, some critical wounds to... View more

View the conversation - Tweetchat: Manag…

Atlantis Healthcare diabetes Tweetchat

Working in partnership, Atlantis Healthcare and pharmaphorum conducted a Tweetchat focussed on the real world challenges patients face in managing... View more

Patient Opinion Leaders: Andrew Schorr


As a cancer survivor and passionate patient advocate, Andrew Schorr typifies the concept of a Patient Opinion Leader (POL). He is a contributor to the... View more

White Papers

Pricing & Market Access Outlook 2014

Pricing & Market Access Outlook 2014

Pricing and market access are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet need,... View info

Getting the most out of technology for m…

Getting the most out of technology for multichannel marketing

While every pharma company recognises the potential of multichannel marketing to optimize its engagement with prescribers, many are yet to implement it to maximum potential. IMS Health explains how a... View info

Anchoring qualitative methodologies in b…

Anchoring qualitative methodologies in business intelligence using smartphone appsPaul Mannu

The use of smartphone apps in market research enables genuine 'in the moment' insight to help us really understand behaviour. Combining this with qualitative methods gives us a deeper insight into behaviours... View info

Opportunities and challenges around non-…

Opportunities and challenges around non-adherence and self‑management in diabetesDr Sinéad NíMhurchadha and Stephen Galt

Diabetes is a chronic condition, the prevalence of which has been escalating around the world for years. The significant consequences this has for healthcare budgets and patient wellbeing is well... View info

Further News & Articles

Pfizer Q3 sound as CEO rules nothing out

Pfizer's Q3 figures were just above projections, with revenues of $12.36 billion against estimates of $12.3 bill... Read more


Ingestible sensor adopted in NHS innovation push

Digital health specialist Proteus has signed a deal that will see its 'smart pill' technology, used to track med... Read more


Charity calls for end to 'inflated' cancer drug prices

A UK cancer charity has criticised the 'inflated' cancer drug prices set by pharma, and also wants the govern... Read more


Sanofi ejects chief executive Viehbacher

Chris Viehbacher has departed from his role as chief executive of Sanofi after the company's board voted to r... Read more


AZ's ovarian cancer drug Lynparza recommended in Europe

A novel PARP inhibitor has received a positive opinion for treating ovarian cancer from the European Medicines A... Read more


Merck's Keytruda granted breakthrough status in lung cancer

Merck's newly launched immunotherapy treatment Keytruda has just been granted special fast-track status for u... Read more